3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Lymphoma, Non-Hodgkin
4
Myelodysplastic Syndromes
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Lymphoma
2
Leukemia
2
Hematologic Neoplasms
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Cardiotoxicity
2
Carcinoma in Situ
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Nose Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Interventions
fludarabine
19
Whole-Body Irradiation
18
Cyclophosphamide
17
fludarabine phosphate
16
ruxolitinib
15
Mycophenolic Acid
14
Specimen Handling
13
Tacrolimus
11
Azacitidine
11
Biopsy
10
Peripheral Blood Stem Cell Transplantation
9
Melphalan
9
Cytarabine
9
venetoclax
8
Sirolimus
8
Busulfan
8
Stem Cell Transplantation
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Daunorubicin
5
Cyclosporine
5
CPX-351
5
luspatercept
4
ivosidenib
4
itacitinib
4
fedratinib
4
decitabine and cedazuridine drug combination
4
Thiotepa
4
Liposomes
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Electrocardiography
×
1 year
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled